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Abstract

Objectives
This pilot study investigated the association of four PET image features and cyclooxygenase-2 (COX-2) expression in patients with oesophageal adenocarcinoma. The prognostic significance of these biomarkers was also assessed.
Methods
Fifty consecutive patients [median age=68 (range 47-84), males=45) with oesophageal adenocarcinoma had PET/CT staging between January 2011 and July 2015. The maximum and mean standardised uptake values (SUVmax and SUVmean), metabolic tumour volume (MTV) and tumour lesion glycolysis (TLG) were calculated from the primary tumour. Their association with COX-2 status was assessed using Mann-Whitney U tests. Kaplan-Meier and Cox regression analysis tested their prognostic significance.
A p-value <0.05 was considered statistically significant.
Results
Thirty-two tumours (64.0%) were COX-2 positive. There was a significant association between SUVmean and COX-2 status (p=0.019). TLG (hazard ratio (HR) 1.001, 95%
confidence intervals (CI) 1.000-1.002, p=0.018) was significantly associated with overall survival on multivariable analysis.
Conclusions
This study investigated the association between PET image features and COX-2 expression in oesophageal adenocarcinoma. The preliminary results signal that a combination of TLG (calculated as product of MTV and SUVmean) and COX-2 status may be a strong and clinically important prognostic biomarker. Our research group are planning a prospective, multi-centre study to validate these findings.
Introduction
The prognosis of oesophageal cancer is poor and adenocarcinoma is the most common histological cell type in developed countries. [1] The development of oesophageal adenocarcinoma has been linked with prolonged mucosal inflammation causing progression through the metaplastic to dysplastic to adenocarcinoma sequence. [2] Cyclo-oxygenase-2 (COX-2) is involved in promoting angiogenesis and is an enzyme that is activated in response to extra-cellular stimuli such as proinflammatory cytokines. [3] It is over-expressed in epithelial solid cancers associated with inflammation. Non-steroidal anti-inflammatory drugs (NSAIDS) may reduce the risk of cancer in the gastrointestinal (GI) tract and aspirin has become the focus of preventative clinical trials. [4] Importantly, COX-2 has been shown to have prognostic significance. [5] Positron emission tomography (PET) combined with computed tomography (CT) using 18-F fluorodeoxyglucose (FDG) is now routinely used in the oesophageal cancer staging pathway. The focus of many PET research studies in oesophageal cancer is the identification of prognostic imaging biomarkers.
Our research group have found that PET image features, maximum and mean standardised uptake value (SUVmax and SUVmean), metabolic tumour volume (MTV) and tumour lesion glycolysis (TLG) have prognostic significance [6] , with similar results confirmed in other studies. [7, 8] Prognostic biomarker studies that correlate immunohistochemical tumour marker expression with imaging biomarkers are currently lacking in oesophageal cancer research, however an association between the SUVmax and COX-2 has been found in lung adenocarcinoma. [9] The discovery of combined prognostic radiological and pathological biomarkers may improve patient risk stratification and treatment decision making. Improved patient selection for more personalised treatment regimens may ultimately improve the currently low survival rates.
Therefore, the primary aim of this pilot study was to obtain preliminary data associating PET image features (SUVmax, SUVmean, MTV and TLG) and COX-2 expression in oesophageal adenocarcinoma. The secondary aim was to assess the prognostic significance of these biomarkers.
Materials & Methods
Patient Selection
This retrospective pilot study considered all consecutive patients with biopsyproven oesophageal and gastro-oesophageal junction adenocarcinoma in a single tertiary centre who had staging PET/CT between January 2011 and July 2015 (n=71). Patients were radiologically staged using the TNM 7 th edition. [10] Given that consecutive patients were studied, the patients included in the study received a variety of surgical, oncological and palliative treatments. (Table 1) Ethical approval was granted to quantify COX-2 expression from archived tissue and correlate with routinely performed PET/CT (REC 14/WA/1208). The requirement for informed consent was waived.
Patients with insufficient archived tissue from the biopsy sample (n=17) and cases in which the primary tumour was non-avid on PET/CT (n=4) were excluded. Fifty patients were included in the study.
PET image features
The standard PET/CT protocol in our centre has previously been published in detail [6] and is included in Appendix 1. This identical protocol was used for each patient in this study. (Fig. 1 ) Data preparation was performed by a single researcher, a radiology resident with 5 years' experience of PET research who was blinded to COX-2 status. Primary oesophageal tumour delineation was performed using the Automatic decision Tree-based Learning Algorithm for Advanced image Segmentation in positron emission tomography (ATLAAS) tool [11] , which eliminates inter-observer variation in tumour outline. SUVmax, SUVmean, MTV and TLG were automatically calculated from the primary tumour only using software developed and validated by our research group. Further details are included in Appendix 1. The SUVmax is the value extracted from the pixel with the highest uptake value in the ATLAAS-defined region of interest.
The SUVmean is calculated as the average uptake value across the MTV. TLG is calculated as the product of SUVmean and MTV.
COX-2 Preparation
COX-2 analysis was performed from archived diagnostic biopsy tissue because this biomarker is not routinely tested during the staging pathway. The tissue was obtained prior to PET/CT and treatment initiation. COX-2 staining was performed on the Leica Bond III automated immunostaining platform and detection carried out using the Leica Bond Polymer Refine DAB system. Primary antibody COX-2 mouse monoclonal (Clone CX-294, (Dako, Ely, UK)) was applied.
COX-2 Quantification
COX-2 expression was quantified by a Consultant Upper GI Histopathologist and classified as a categorical variable based on the intensity of staining using the following grading: 0, 1+, 2+ and 3+. [12] (Fig. 2) A grading of 0/1+ was considered negative and 2+/3+ considered positive. A pre-constructed control tissue microarray (TMA) was added to the slides as a control with standardised 3+, 2+, 1+ and 0 scoring tumour for COX-2. Internal negative controls within non-tumour components of the biopsies were also tested.
Survival Data
The secondary outcome of the study was overall survival, defined in months from the data of diagnosis. No patient was lost to follow-up, with each patient receiving clinical follow-up 3-monthly in the first year, then 6-monthly thereafter for the next 4 years, or until death.
Statistical analysis
Categorical variables were described as frequency (percent) and continuous variables as median (range). Mann-Whitney U tests were used to assess for significant differences between PET image features and COX-2. Chi-square Statistical analysis was performed using SPSS v23.0 (IBM, Chicago, USA).
Results
Patient Cohort
Baseline characteristics of the patient cohort are detailed in Table 1 
Association of TNM Stage and PET Image Features with COX-2 Status
SUVmean (U=172.0, mean rank 31.9 vs 21.9, p=0.019) showed a significant association with COX-2 status. (Fig. 3) A higher grade of COX-2 expression correlated with a lower SUVmean value. SUVmax, MTV and TLG did not reach statistical significance with COX-2 status (p=0.079, p=0.486 and p=0.203, respectively). COX-2 expression is prognostically significant. In one systematic review and meta-analysis in oesophageal adenocarcinoma, COX-2 had the largest survival effect (HR 2.47, 95% CI 1.15-3.79) out of 9 tumour markers including human epidermal receptor growth factor 2 (HER-2) and Ki-67. [5] In this current study, MTV on univariable and TLG on multivariable analyses were significantly associated with overall survival. These results support other published research. [7] As expected, disease stage was also significantly associated with overall survival. Tumours with larger MTV and higher FDG-uptake are likely to indicate more advanced tumours and therefore be associated with poorer outcomes. Although COX-2 was not prognostically significant in this patient cohort, preliminary data was obtained from 50 consecutive patients only. This pilot study is under-powered to detect this difference and a larger cohort may have demonstrated statistical significance between COX-2 status groups. In addition, treatment regimens did not influence survival differences between these groups, with relatively equal proportions of patients receiving radical or palliative treatments.
Prognostic Significance of TNM Stage, PET Image Features and COX-2 Status
Given the proven link of increased cancer risk with inflammation, the association with COX-2 status and FDG-uptake on PET could signal the potential for clinically important combined biomarkers. Aspirin has become the focus of preventative clinical trials given the link between non-steroidal antiinflammatory drug (NSAID) use and inflammation in cancer. [4] COX-2 is thought to be over-expressed in areas of inflammation such as segments of Barrett's oesophagus. [2] Our research group is planning a prospective, multicentre study to further investigate and validate the association of COX-2 status and PET image features in oesophageal adenocarcinoma. Such research should follow the key recommendations outlined in the imaging biomarker roadmap for cancer studies, which describes the necessary stages in the translational pathway of potential image biomarkers from discovery to validation and adoption into clinical practice. [17] This pilot study had several strengths. All patients underwent PET/CT using an identical protocol and scanner. This sample of patients were treated as part of a large, experienced Regional Upper GI cancer MDT, serving a population of over 1.4 million. All diagnostic biopsies and tumour markers were evaluated by a Consultant GI Histopathologist. No patients were lost to follow-up.
Limitations
This retrospective, single centre pilot study with a small patient cohort has a number of limitations which should be addressed in future studies. As for similar studies involving biopsy data, it is possible that results are affected by differences in tumour marker expression between the sample and the whole imaged tumour volume. Multiple populations of clonal cells are known to exist within tumours, therefore independent biopsies sampling different regions of malignant tissue may result in varying levels of tumour marker expression. In addition, tumour marker analysis was conducted from archived tissue. Older tissue may degrade affecting its quality and quantity [18] but cases in which there was insufficient tissue were excluded from this study. The oldest biopsy in our cohort was 4 years old.
Conclusion
This pilot study associated PET image features and COX-2 expression in oesophageal adenocarcinoma. This study provides preliminary evidence that SUVmean is associated with COX-2 status and further evidence that MTV and TLG are prognostically significant. These findings suggest that further research is warranted and will inform a prospective, multi-centre study investigating PET image features and COX-2 expression. 
